HOME › DRUGS › ALLOGENEIC T CELLS GENETICALLY MODIFIED WITH A RETROVIRAL VECTOR ENCODING FOR A TRUNCATED FORM OF THE HUMAN LOW AFFINITY NERVE GROWTH FACTOR RECEPTOR (ΔLNGFR) AND THE HERPES SIMPLEX I VIRUS THYMIDINE KINASE (HSV-TK MUT2)
ACTIVE SUBSTANCE / INN

ALLOGENEIC T CELLS GENETICALLY MODIFIED WITH A RETROVIRAL VECTOR ENCODING FOR A TRUNCATED FORM OF THE HUMAN LOW AFFINITY NERVE GROWTH FACTOR RECEPTOR (ΔLNGFR) AND THE HERPES SIMPLEX I VIRUS THYMIDINE KINASE (HSV-TK MUT2)

Brand name(s): Zalmoxis
EMA LISTED
WITHDRAWN
Hematopoietic Stem Cell Transplantation;Graft vs Host Diseas…
ACTIVE SUBSTANCE
Allogeneic T Cells Genetically Modified With A Retroviral Vector Encoding For A Truncated Form Of The Human Low Affinity Nerve Growth Factor Receptor (Δlngfr) And The Herpes Simplex I Virus Thymidine Kinase (Hsv-Tk Mut2)
REGULATORS
EMA
SPONSORS / MAH
MolMed SpA
TOTAL APPLICATIONS
1
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
ZalmoxisMolMed SpAWithdrawn18/08/2016Hematopoietic Stem Cell Transplantation;Graft vs Host Disease

FULL INTELLIGENCE ON ALLOGENEIC T CELLS GENETICALLY MODIFIED WITH A RETROVIRAL VECTOR ENCODING FOR A TRUNCATED FORM OF THE HUMAN LOW AFFINITY NERVE GROWTH FACTOR RECEPTOR (ΔLNGFR) AND THE HERPES SIMPLEX I VIRUS THYMIDINE KINASE (HSV-TK MUT2)

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →